Sep 23 2015
Stereotaxis, Inc., a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that J. David Burkhardt, M.D. of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center in Austin, TX has surpassed 1,000 electrophysiology (EP) procedures performed with the Niobe® remote magnetic navigation system.
Dr. Burkhardt is the first in the U.S. to achieve this significant milestone and one of the top five Niobe system users globally. More than 82,000 procedures have been conducted worldwide with the Niobe system.
"I rely on the Niobe system implicitly for my complex EP procedures," said Dr. Burkhardt, who primarily treats complex arrhythmias and is considered an expert in the ablation of VT (ventricular tachycardia) and other complex arrhythmias. "At St. David's, we maintain a high standard of excellence and are committed to employing the most state-of-the-art tools to improve the quality of life for our patients. Stereotaxis' advanced, computer-controlled technology has allowed us to perform very complicated procedures safely and efficiently, and we have published excellent results using the system. In addition, we are able to reach areas of the heart that otherwise would not have been possible. As a result, we have achieved safer, higher quality ablations with the Niobe system compared to other approaches."
Under the leadership of Executive Medical Director Dr. Andrea Natale, a world renowned EP professional, St. David's Medical Center installed the Niobe system in 2009, becoming the first facility in central Texas to implement Stereotaxis technology. St. David's has since adopted it as the standard of care for patients diagnosed with VT. After upgrading to the Niobe® ES system in 2011, Dr. Burkhardt described the new platform and compatible soft magnetic catheter as "able to optimize patient safety and navigate difficult cases with precision."
Dr. Natale, Dr. Burkhardt, and the rest of the TCAI team are at the forefront of advancing treatment for cardiac arrhythmias and are looked to as trusted advisors by EP physicians from around the world. In addition to the numerous clinical studies previously released by TCAI on the effectiveness of Stereotaxis' remote magnetic navigation technology, the upcoming American Heart Association Scientific Sessions in November will publish the latest TCAI research results on long-term outcomes of the treatment of VT using Stereotaxis technology.